Carbapenem resistant Enterobacteriaceae - second update
Carbapenem resistance in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli poses a significant threat to patients and healthcare systems in all European Union/European Economic Area (EU/EEA) countries. Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of treatment options. Hypervirulent carbapenem-resistant K. pneumoniae strains have been reported presenting an additional threat with a potential for global dissemination. The spread of high risk clones and plasmids carrying carbapenemases in healthcare settings is a major cause of the spread of CRE in EU/EEA countries. Recent events of cross-border importation after patient transfer and large regional outbreaks as well as the worsening epidemiologic situation of carbapenemase-producing CRE in the EU/EEA highlight the high risk for further spread of CRE and the need for enhanced control efforts. Options for control are outlined in the respective section below.
Find facts, infographics, data, scientific advice and guidance on antimicrobial resistance.Read more
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae - first update
7 Jun 2018 - This update of the 2016 ECDC Rapid Risk Assessment on carbapenem-resistant Enterobacteriaceae (CRE) evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.